Cargando…

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved exciting results. Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Shengnan, Yi, Ming, Qin, Shuang, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701025/ https://www.ncbi.nlm.nih.gov/pubmed/31429760 http://dx.doi.org/10.1186/s12943-019-1057-4

Ejemplares similares

Chimeric antigen receptor T cells: a novel therapy for solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
por: Petty, Amy J., et al.
Publicado: (2020)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

Toxicity of Chimeric Antigen Receptor T Cells and its Management
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds
por: Kalos, Michael
Publicado: (2016)

Generation of hypoxia-sensing chimeric antigen receptor T cells
por: Kosti, Paris, et al.
Publicado: (2021)

Generation of Chimeric Antigen Receptors against Tetraspanin 7
por: Pieper, Tom, et al.
Publicado: (2023)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
por: Sawaisorn, Piamsiri, et al.
Publicado: (2020)

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
por: Tian, Meijie, et al.
Publicado: (2022)

Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies
por: Schorr, Christopher, et al.
Publicado: (2023)

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
por: Li, Hua, et al.
Publicado: (2017)

The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
por: Davey, Ashleigh S., et al.
Publicado: (2020)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

A compound chimeric antigen receptor strategy for targeting multiple myeloma
por: Chen, K H, et al.
Publicado: (2018)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
por: Casucci, Monica, et al.
Publicado: (2011)

Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
por: Bonaldo, Giulia, et al.
Publicado: (2021)

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
por: Yang, Yingying, et al.
Publicado: (2018)

The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal Late-Stage T Cells
por: Rappl, Gunter, et al.
Publicado: (2012)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
por: Xiong, Wei, et al.
Publicado: (2018)

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
por: Xiong, Wei, et al.
Publicado: (2021)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure
por: Li, Shuang, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_isrn5kcqgdm38bn51lvoplvcdp